AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02063724 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HER-2 pulsed Dendritic Cell Vaccine
Description: 6 weekly HER-2 pulsed dendritic cell vaccines followed by 3 booster vaccines once every 3 months. Each dose will consist of between 1.0-2.0 x 10\^7 cells and will be injected into 1-2 different normal groin lymph nodes or axillary nodes.
Study NCT03309306 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Natural Environment/Stress Management
Description: Participants will use the FoodImage app to capture data on food purchases, food waste that occurs during food preparation, food waste that is present after eating, and food waste from food purges in free-living conditions. Participants will capture baseline data for 4-7 days. After a 1-week break, participants will use the app to record food waste for approximately 4-7 days over the subsequent week. They will also receive information on stress management
Study NCT01770145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethobenzamide
Description: Following the L-Dopa Baseline Period, subjects will initiate trimethobenzamide treatment TID for a minimum of 3 days during a Anti-Emetic Pretreatment Period. Subjects will continue trimethobenzamide therapy TID through the duration of the APOKYN Initiation Period and APOKYN Treatment Period.
Study NCT05942170 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ICG/ blue dye
Description: The SLN mapping procedure was performed as previously described by using IGC or blue dye. The injection technique of the tracers was the same for both cervical and endometrial cancer. The cervical injection was done by insulin syringe(one ml) inserting full needle length (1 cm) and complete injection at 3, 9 o'clock, or 2,4,8,10 o'clock.
Study NCT02305550 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electrical pulsed plasma discharge synthesis of nitric oxide
Description: An NO generator was designed and developed by electrical pulsed plasma discharge nitric oxide from atmospheric nitrogen and oxygen. This generator has been fabricated by the investigators and it is not commercially available.
Study NCT02676453 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Dental hygienist support
Study NCT03249701 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Acupoint Stimulation
Description: The intervention will be administered by electrical acupoint machine, the brand is Great Wall.
Study NCT03249701 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Electroacupuncture
Description: The intervention will be administered by electrical acupoint machine, the brand is Great Wall.
Study NCT03249701 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham Transcutaneous Electrical Acupoint Stimulation
Description: The intervention will be administered by transcutaneous electrical acupoint machine, even no truly actualized.
Study NCT00914238 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 2 years OPUS treatment
Description: 2 years OPUS and transfer to standard treatment.
Study NCT00914238 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OPUS 5 years
Study NCT05145673 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (OGTT)
Description: The control group was given an glucose solution to oral glucose tolerance test (OGTT) The glucose solution consist in a glucose drink with 75g of anhydrous D-Glucose dissolved in 200 mL of water at room temperature, as prescribed by ADA. The blood glucose levels were measured before intervention at fasting (t0) and after 30 (t30), 60 (t60, 90 (t90) and 120 (t120) minutes after intervention from both groups.
Study NCT05145673 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cinnamon (OGTT plus aqueous cinnamon extract)
Description: The intervention group was given an glucose solution to OGTT followed by a cinnamon aqueous extract. The glucose solution consist in a glucose drink with 75g of anhydrous D-Glucose dissolved in 200 mL of water at room temperature, as prescribed by ADA. The blood glucose levels were measured before intervention at fasting (t0) and after 30 (t30), 60 (t60, 90 (t90) and 120 (t120) minutes after intervention from both groups.
Study NCT03945448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose liposomal Amphotericin and Fluconazole
Description: Intravenous Single dose of 10mg/kg of Ambisome and fluconazole as per WHO guidelines for six months.
Study NCT03945448 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluconazole
Description: Fluconazole 800mg for 2 weeks,400mg for 8 weeks and 200mg up to six months
Study NCT02668952 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% Normal Saline (0.9% Sodium Chloride) injection
Study NCT02668952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isolyte S injection
Study NCT04125303 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: brief motivational psychoeducational therapy
Description: The brief motivational psychoeducational therapy (BMPT) it lasted an average of 90 min and followed the following structure: (i) brainstorming the concepts of health, lifestyle, and substance-use prevention; (ii) analysis of a work accident at an international rock group concert, which was used to generate (iii), a debate on consumer habits (30 min); (iv) discussion of the substance types and classifications known by the participants; (v) Prochaska and DiClemente's stages of change and (vi), the consequences of drug use (50 min); and finally, (vii) a true/false quiz used to discuss myths and beliefs about drugs (10 min).
Study NCT01606007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin XR
Description: Tablets, Oral, ≥ 1500mg/≤ 2000mg, Once daily, 24 weeks
Study NCT01606007 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: Tablets, Oral, 10mg , Once daily, 24 weeks
Study NCT01606007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablets, Oral, 10mg , Once daily, 24 weeks
Study NCT01606007 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo matching with Dapagliflozin
Description: Tablets, Oral, 0mg, Once daily, 24 weeks
Study NCT01606007 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo matching with Saxagliptin
Description: Tablets, Oral, 0mg, Once daily, 24 weeks
Study NCT03266965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbidopa
Description: All subjects will receive a fixed dose of 50mg of Lodosyn twice daily.
Study NCT03266965 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-Histidine
Description: Sequential Dose Escalation of 250mg to 500mg to 1000mg twice daily.
Study NCT03953885 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fire needle
Description: 1. Participants wear eye masks and fully expose the lesions. After selecting the acupuncture points, the surgeon routinely disinfects the hands of the operator and the acupuncture points of the participants before the operation. After selecting an acupuncture needle with a specification of 0.4\*40mm and ignites the alcohol lamp, the operator continuously moves the needle from the needle root to the needle tip to burn the red needle to disinfect the needle in the outer flame of the alcohol lamp.~2. The operator ignites the alcohol lamp, and burns the needle tip and the needle body to the outer flame of the alcohol lamp until it is completely red (the length of the needle burning red is determined by the acupuncture depth), and then rapidly penetrates the skin lesion vertically, the depth of the acupuncture is based on the thickness of the skin lesion, when the operation is performed, the outer edge of the lesion is punctured to the center point, and the spacing is 0.3 to 0.5 cm.
Study NCT03953885 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Fire needle Placebo
Description: 1. Participants wear eye masks and fully expose the lesions (no lesions on the head and face, external genitalia and skin folds). After selecting the acupuncture points, the surgeon routinely disinfects the hands of the operator and the acupuncture points of the participants before the operation, then selects an acupuncture needle with a specification of 0.4\*40mm to prepare for operation.~2. The operator rapidly penetrates the skin lesion vertically, the depth of the acupuncture is based on the thickness of the skin lesion, when the operation is performed, the outer edge of the lesion is punctured to the center point, and the spacing is 0.3 to 0.5 cm.
Study NCT02772224 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug eluting balloon angioplasty
Description: In the DEB group, the guide wire will be passed through the occluded or stenosed lumen and the predilatation of the target lesion with standard balloon(s) will be performed before dilatation with a paclitaxel-eluting balloon of the diameter, at least about that of the pre-dilatation balloon (Arteryguard, Rientech, Dezhou, China). The drug eluting balloons will then be inflated according to the manufacturer recommendations. The patients will then be followed every six months for a year to compare its treatment efficacy and safety with that of conventional balloon angioplasty group.
Study NCT02772224 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional balloon angioplasty
Description: The guide wire will be passed through the occluded or stenosed lumen and the conventional balloons will be inflated as recommended by the manufacturer. The primary and secondary outcome will then be assessed and compared with DEB group, on follow up at six and 12 months.
Study NCT02637804 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: stenfilcon A
Description: contact lens
Study NCT02637804 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: narafilcon A
Description: contact lens
Study NCT02637804 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: delefilcon A
Description: contact lens
Study NCT05872698 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol
Description: Carvedilol, sold under the brand name Coreg among others, is a medication used to treat high blood pressure, congestive heart failure, and left ventricular dysfunction in people who are otherwise stable. For high blood pressure, it is generally a second-line treatment. It is taken by mouth.
Study NCT05872698 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02798133 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: OLA
Description: PEEP titration trial for best Cdyn after the alveolar recruitment maneuver
Study NCT02798133 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RM-5
Description: Fixed standard PEEP after the alveolar recruitment maneuver
Study NCT03824613 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Urinary miRNA
Description: MiRNA detection in urine
Study NCT01374191 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: onabotulinum toxin type-A
Description: 1 injection of Btx-A
Study NCT01374191 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 injection of saline solution
Study NCT01374191 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2nd phase - onabotulinum toxin type-A
Description: 2 - 3 injections of Btx-A, specific to patient pain recurrence
Study NCT03634176 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: optical nerve sheet diameter
Description: The ONSD in each eye was measured vertically and horizontally 3 mm behind the optic disc, with the two values averaged. No pressure was applied to the orbit. At each time point, measurements were taken within 5 min. The measurements were made before (T1) and after some of the strategies according to group 30 min (T2), 60 min (T3), and 90 min (T4).
Study NCT02325960 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: exenatide
Description: 5 μg BID for the first 4 weeks of treatment and 10 μg thereafter.
Study NCT02325960 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine
Description: ≥8 IU QD, and titrate based on a dosing algorithm targeting FPG \<6.1 mmol/L. Titration is only allowed in first 4 weeks.
Study NCT01131754 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: heparin 100U/L flushes
Description: peripheral venous catheter flushing with 3 mL of a 100 U heparin/mL normal saline from mono-use vial (Epsodilave, Mayne Pharma, Naples, Italy) at the end of each drug infusion. Independently from the number of drug infusions, all patients will receive at least two catheter flushes every day.
Study NCT01131754 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: heparin 100U/L flushes
Description: peripheral venous catheter flushing with 3 mL of a 100 U heparin/mL normal saline from mono-use vial (Epsodilave, Mayne Pharma, Naples, Italy) at the end of each drug infusion. Independently from the number of drug infusions, all patients will receive at least two catheter flushes every day.
Study NCT01949558 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Study NCT01230632 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: high fat overfeeding
Description: Dietary Supplement:3 days overfeeding
Study NCT06498492 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic Cholecystectomy
Description: Laparoscopic cholecystectomy (LC) has been established as the gold standard of treatment for acute mild biliary pancreatitis.
Study NCT02792972 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: A. oleracea
Description: The plant extract A. oleracea manipulated with Transcutol® were used in the volunteers before the venipuncture procedure as allocation in study groups. Held collection of skin microbiota by the swab technique and the end of the venipuncture procedure was applied to the volunteer, the visual numeric scale (VNS) standard to determine the degree of pain.
Study NCT02792972 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 70% alcohol
Description: 70% alcohol were used in the volunteers before the venipuncture procedure as allocation in study groups. Held collection of skin microbiota by the swab technique and the end of the venipuncture procedure was applied to the volunteer, the visual numeric scale (VNS) standard to determine the degree of pain.
Study NCT01599572 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: zinc supplementation
Description: 30mg/day of zinc in the form of zinc gluconate
Study NCT01463124 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lookin' Good Feelin' Good
Description: Six 30-minute individual student-centered counseling sessions delivered by school nurses during the first two months followed by weekly weigh-ins and monthly visits over the subsequent 6 months, plus an exercise program in the school 3 times a week for the full eight months of the intervention.
Study NCT01463124 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information attention-control
Description: Six individual sessions with school nurse over the first two months followed by monthly visits over the remaining 6 months to check weight and behavior changes and provide a series of pamphlets on weight and weight management.
Study NCT00646750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ybritumomab Tiuxetan (Zevalin); Rituximab; BEAM (BCNU, ARAC, VP16 and Melphalan)
Description: Day -21: rituximab. 250 mg/m2 iv~Day -14: rituximab. 250 mg/m2 plus Ybritumomab Tiuxetan (Zevalin)(0.4 mCi/kg maximum dose 32 mCi).~Days -6 to -1: BEAM regimen as follows BCNU: 300 mg/m2 over 2 hours, day -6. ARAC: 200 mg/m2/12 hours over 12 hours, days -5 through -2. VP16: 200 mg/m2/day over 2 hours, days -5 through -2. Melphalan: 140 mg/m2/day over 15 minutes, day -1.
Study NCT02380482 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Transthoracic echocardiography on TBI patients
Description: Two Dimensional and speckle trackingTransthoracic echocardiography on TBI patients within 24 hours of trauma
Study NCT02380482 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Transthoracic echocardiography on control patients
Description: Two Dimensional and speckle trackingTransthoracic echocardiography on control patients while intubated-ventilated
Study NCT03396640 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Unicondylar Knee Arthroplasty
Description: Incision will be midline incision, as with a TKA, for maximum security of blinding.~Standard operative technique will hereafter be used, with minor individual preferences for each surgeon as to whether tourniquet/not, drain or not.
Study NCT03396640 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Knee Arthroplasty
Description: Incision will be midline incision, as standard. Standard operative technique will hereafter be used, with minor individual preferences for each surgeon as to whether tourniquet/not, drain or not.
Study NCT00262639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flumazenil and Gabapentin
Description: 2 mg flumazenil for infusion given slowly over 20 minutes given day 1 and day 2 gabapentin 300 mg increasing to 1200 mg over 4 days and continuing to day 30. Gabapentin 900 mg Day 31 to Day 33 gabapentin 600 mg Day 34 to 36 and gabapentin 300 mg Day 37 to 39.
Study NCT00262639 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Flumazenil and Gabapentin
Description: 2 mg flumazenil for infusion given slowly over 20 minutes given day 1 and day 2 gabapentin 300 mg increasing to 1200 mg over 4 days and continuing to day 30. Gabapentin 900 mg Day 31 to Day 33 gabapentin 600 mg Day 34 to 36 and gabapentin 300 mg Day 37 to 39.
Study NCT02043587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 IV once daily on days 1 \& 15 (precursor B-cell ALL only, administer per institutional protocol) during Courses 1A, 1B, 1C \& 2A
Study NCT02043587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Randomize patients proceeding to Course 1B to hydrocortisone versus placebo prior to PEG-asparaginase treatments in Courses 1B, 2B, 3B, and Maintenance month 1
Study NCT01709253 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: proton beam therapy
Description: hypofractionation study using proton beam therapy for prostate adenocarcinoma
Study NCT02299115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Corticosteroid
Study NCT02299115 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vigabatrin
Description: Antiepileptic
Study NCT04365218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI8367
Description: Subjects will receive subcutaneous (SC) single dose of MEDI8367, depending upon dose escalation strategy and Safety Review Committee results. The maximum dose will not exceed 600 mg. The dose will be administered as a single injection or multiple injections in the abdomen region.
Study NCT04365218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Saline solution for injection and the placebo volume to be administered will be equivalent to the MEDI8367 volume administered for each dosing cohort.
Study NCT04439695 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dose
Description: Low dose of KBP-V001
Study NCT04439695 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intermediate dose
Description: Intermediate dose of KBP-V001
Study NCT04439695 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dose
Description: High dose of KBP-V001
Study NCT04439695 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Buffered Saline Solution
Study NCT02832180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OC containing EE and NET
Study NCT02832180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986142
Study NCT01062867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORG25435
Description: Intended doses: 0.25, 0.5, 1.0, 2.0, 3.0, 4.0, 5.0 and 6.0 mg/kg by intravenous infusion over 1 min Up to 25mg/kg by infusion over 30min
Study NCT02879734 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prophylactic laparoscopic omentopexy
Description: Fixation of omentum with sutures to anterior abdominal wall during laparoscopic surgery
Study NCT02566356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: 40 IU of the oxytocin will be administered intranasally for a one time dose at the beginning of the visit.
Study NCT02566356 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Nasal Spray
Description: 40 IU of the saline nasal spray will be administered once at the beginning of the visit.
Study NCT02552212 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Certolizumab Pegol
Description: * Active Substance: Certolizumab Pegol~* Pharmaceutical Form: Prefilled syringe~* Concentration: 200 mg / ml~* Route of Administration: Subcutaneous injection
Study NCT02552212 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * Active Substance: Placebo~* Pharmaceutical Form: Prefilled syringe~* Concentration: 0.9 % saline~* Route of Administration: Subcutaneous injection
Study NCT00370812 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: amniotic membrane transplantation
Description: AMT with conventional medical therapy (group A) or medical treatment only (group B). AMT will be performed within 24h of presentation. Amniotic membrane will remain in place for 7-14 days.
Study NCT03626883 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: single-bundle, single-hamstring ACL reconstruction
Description: anterior cruciate ligament reconstruction with single hamstring tendon